|
1.
|
Okuda K: Hepatocellular carcinoma. J
Hepatol. 32:225–237. 2000. View Article : Google Scholar
|
|
2.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lee JH, Chung YH, Kim JA, et al: Genetic
predisposition of hand-foot skin reaction after sorafenib therapy
in patients with hepatocellular carcinoma. Cancer. 119:136–142.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sauer G, Kafka A, Grundmann R, Kreienberg
R, Zeillinger R and Deissler H: Basal expression of the multidrug
resistance gene 1 (MDR-1) is associated with the TT genotype at the
polymorphic site C3435T in mammary and ovarian carcinoma cell
lines. Cancer Lett. 185:79–85. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ling V: Multidrug resistance and
P-glycoprotein expression. Ann NY Acad Sci. 507:7–8. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Roninson IB, Chin JE, Choi KG, et al:
Isolation of human mdr DNA sequences amplified in
multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA.
83:4538–4542. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chambers I, Colby D, Robertson M, Nichols
J, Lee S, Tweedie S and Smith A: Functional expression cloning of
Nanog, a pluripotency sustaining factor in embryonic stem cells.
Cell. 113:643–655. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Mitsui K, Tokuzawa Y, Itoh H, et al: The
homeoprotein Nanog is required for maintenance of pluripotency in
mouse epiblast and ES cells. Cell. 113:631–642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Freberg CT, Dahl JA, Timoskainen S and
Collas P: Epigenetic reprogramming of OCT4 and NANOG regulatory
regions by embryonal carcinoma cell extract. Mol Biol Cell.
18:1543–1553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Gu G, Yuan J, Wills M and Kasper S:
Prostate cancer cells with stem cell characteristics reconstitute
the original human tumor in vivo. Cancer Res. 67:4807–4815. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Zbinden M, Duquet A, Lorente-Trigos A,
Ngwabyt SN, Borges I and Ruiz i Altaba A: NANOG regulates glioma
stem cells and is essential in vivo acting in a cross-functional
network with GLI1 and p53. EMBO J. 29:2659–2674. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Seigel GM, Hackam AS, Ganguly A, Mandell
LM and Gonzalez-Fernandez F: Human embryonic and neuronal stem cell
markers in retinoblastoma. Mol Vis. 13:823–832. 2007.PubMed/NCBI
|
|
14.
|
Meng HM, Zheng P, Wang XY, et al:
Overexpression of nanog predicts tumor progression and poor
prognosis in colorectal cancer. Cancer Biol Ther. 9:295–302. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Jeter CR, Badeaux M, Choy G, et al:
Functional evidence that the self-renewal gene NANOG regulates
human tumor development. Stem Cells. 27:993–1005. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jeter CR, Liu B, Liu X, et al: NANOG
promotes cancer stem cell characteristics and prostate cancer
resistance to androgen deprivation. Oncogene. 30:3833–3845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Du Y, Shi L, Wang T, Liu Z and Wang Z:
Nanog siRNA plus Cisplatin may enhance the sensitivity of
chemotherapy in esophageal cancer. J Cancer Res Clin Oncol.
138:1759–1767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Dalerba P, Cho RW and Clarke MF: Cancer
stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Dalerba P and Clarke MF: Cancer stem cells
and tumor metastasis: first steps into uncharted territory. Cell
Stem Cell. 1:241–242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Yu F, Yao H, Zhu P, et al: let-7 regulates
self renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Xu XL, Xing BC, Han HB, et al: The
properties of tumor-initiating cells from a hepatocellular
carcinoma patient’s primary and recurrent tumor. Carcinogenesis.
31:167–174. 2010.
|
|
22.
|
Al-Hajj M: Cancer stem cells and oncology
therapeutics. Curr Opin Oncol. 19:61–64. 2007.PubMed/NCBI
|
|
23.
|
Boyer LA, Lee TI, Cole MF, et al: Core
transcriptional regulatory circuitry in human embryonic stem cells.
Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Tang Y, Kitisin K, Jogunoori W, et al:
Progenitor/stem cells give rise to liver cancer due to aberrant
TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 105:2445–2450.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lin YL, Han ZB, Xiong FY, et al: Malignant
transformation of 293 cells induced by ectopic expression of human
Nanog. Mol Cell Biochem. 351:109–116. 2011. View Article : Google Scholar
|
|
26.
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24(+) liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011.
|
|
27.
|
Shan J, Shen J, Liu L, et al: Nanog
regulates self-renewal of cancer stem cells through the
insulin-like growth factor pathway in human hepatocellular
carcinoma. Hepatology. 56:1004–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Xin H, Kong Y, Jiang X, et al:
Multi-drug-resistant cells enriched from chronic myeloid leukemia
cells by Doxorubicin possess tumor-initiating-cell properties. J
Pharmacol Sci. 122:299–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Pérez-Tomás R: Multidrug resistance:
retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006.PubMed/NCBI
|
|
30.
|
Goda K, Bacsó Z and Szabó G: Multidrug
resistance through the spectacle of P-glycoprotein. Curr Cancer
Drug Targets. 9:281–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lage H: MDR1/P-glycoprotein (ABCB1) as
target for RNA interference-mediated reversal of multidrug
resistance. Curr Drug Targets. 7:813–821. 2006. View Article : Google Scholar
|
|
32.
|
He Y, Bi Y, Hua Y, et al: Ultrasound
microbubble-mediated delivery of the siRNAs targeting MDR1 reduces
drug resistance of yolk sac carcinoma L2 cells. J Exp Clin Cancer
Res. 30:1042011. View Article : Google Scholar : PubMed/NCBI
|
